The FDA ODAC decided that the overall benefit-risk of the investigational therapy UGN-102 is not favorable in patients with ...

Manmeet Ahluwalia, MD, MBA, FASCO, discussed the importance of Brain Cancer Awareness Month for a community oncologist ...

A panelist discusses how the CABINET trial showed significant progression-free survival benefits for cabozantinib compared with placebo (particularly in pancreatic neuroendocrine tumors (NETs), why ...

A panelist discusses how the CABINET trial was a National Cancer Institute (NCI)–supported study conducted by the Alliance for Clinical Trials in Oncology that enrolled patients with ...

During a live event, Nathan M. Denlinger, DO, MS, discussed the PILOT and ALYCANTE trials of CAR T-cell therapy in transplant-ineligible B-cell lymphoma.

In a 6 to 2 vote, the Oncologic Drug Advisory Committee determined that findings from the phase 3 AQUILA trial do/do not ...

Roger Li, MD, discusses factors influencing international doctors' attendance at the upcoming American Society of Clinical ...

Roger Li, MD, discusses the MoonRISe-1 study evaluating TAR-210 in FGFR-altered intermediate-risk non-muscle-invasive bladder cancer.

John L. Marshall, MD, discusses unmet needs in the targeted therapy space and the importance of optimizing dosing in colorectal cancer.

In an interview with Targeted Oncology, C. Ola Langren, MD, discussed the continuing impact of the groundbreaking FDA ODAC ...

PT-112 monotherapy advances to phase 3 trial in metastatic castration-resistant prostate cancer after positive FDA end of ...

In an 8 to 1 vote, the Oncologic Drug Advisory Committee determined that findings from the phase 3 STARGLO trial are not applicable to patients in the US with diffuse large B-cell lymphoma.